Healthcare
With the positive results from this trial, as well as an earlier Phase III trial, Myovant Sciences plans to seek regulatory approval later this year.
Myxredlin is intended for use only in acute care settings under medical supervision.
Researchers at UC Davis Health identified a new molecular link that could potentially lead to new diabetes treatments and potential cardiovascular therapies. They published their research in The Journal of Clinical Investigation.
Scientists have long known that our environment can affect the way our genes work, a process called gene expression.
As the beta-amyloid theory of Alzheimer’s disease fades from prominence, many researchers are turning their attention to the role of inflammation. Although beta-amyloid is still very much a factor in the disease, many believe that it is an uncontrolled or faulty inflammatory and immune reaction to beta-amyloid that causes the majority of the cognitive damage.
The National Institute of Health Research has announced £135m of funding for new research projects across the UK to tackle some of the biggest health conditions, including dementia.
Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.
Part of the problem with developing Alzheimer’s drugs has also been that the disease is still not well understood. What is known is that problems with cellular functions and/or improperly functioning proteins cause brain cells, called neurons, to become damaged, leading to their decreased function and eventually death.
Reston Hospital Center has received the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Gold Plus Quality Achievement Award.
Construction to host IBA’s Proteus®ONE system expected to start later this year
PRESS RELEASES